A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma
David P. Ryan(East Carolina University), Jeffrey W. Clark(Massachusetts General Hospital), Steven R. Grossman(Virginia Commonwealth University), Haesook Kim(Dana-Farber Cancer Institute), Matthew H. Kulke(Moffitt Cancer Center), Craig C. Earle(Canadian Partnership Against Cancer), Charles S. Fuchs(University of Southern California), Robert J. Mayer(Applied Natural Sciences), Ramesh A. Shivdasani(Harvard University), Jeffrey A. Morgan(Sheba Medical Center), Michael L. Grossbard(NYU Langone Health)
Cited by 94
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k